Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
Vir Biotechnology, Inc. (VIR) has a notice from former officer Jason V. O'Byrne covering planned sales of common stock under Rule 144. The notice lists multiple tranches of common shares to be sold that were or will be acquired through restricted stock vesting on November 15, 2025, November 28, 2025, February 23, 2026, and February 24, 2026, and through an ESPP purchase on May 29, 2026. It also reports that O'Byrne has already sold several blocks of Vir common stock in recent months, including 25,000 shares for $245,297.50 on August 21, 2026, and additional sales on August 24, August 25, and September 9, 2026.
Vir Biotechnology, Inc. (VIR) received a notice under Rule 144 that former officer Jason V. O'Byrne, through Fidelity Brokerage Services LLC, intends to sell 28,333 shares of common stock, expected to be issued from a stock option exercise on September 9, 2026. The filing lists an estimated aggregate sale price of $315,241.24 and states that 169,215,958 shares of common stock were outstanding as of September 9, 2026.
The notice also reports prior sales of Vir common stock for O'Byrne during the past three months, including transactions on August 21, 24, and 25, 2026.
Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by Jason V. O'Byrne, identified as a former officer, under Rule 144. The notice covers up to 23,148 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $242,591.04. Vir Biotechnology reports 169,215,958 shares of common stock outstanding as of 08/25/2026. In the prior three months, Jason V. O'Byrne sold 25,000 shares for $245,297.50 on 08/21/2026 and 14,352 shares for $142,123.55 on 08/24/2026. The planned sale is in connection with a stock option exercise, with sales expected on or about 08/25/2026 on NASDAQ.
Vir Biotechnology, Inc. (VIR) is the issuer for a planned sale of common stock by former officer Jason V. O'Byrne under Rule 144. The notice lists up to 14,352 shares of common stock to be sold, with an aggregate market value of $142,124.00, following a stock option exercise for cash on 08/24/2026. The securities are held at Fidelity Brokerage Services LLC and are listed on NASDAQ. The notice also reports that O'Byrne sold 25,000 shares of Vir common stock during the past three months for proceeds of $245,297.50.
Vir Biotechnology, Inc. (VIR) is the issuer of common stock that a former officer, Jason V. O'Byrne, has notified under Rule 144 may be sold. The notice covers up to 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or after 08/21/2026, in connection with a stock option exercise.
Vir Biotechnology, Inc. director Robert J. More reported entity-level share transfers involving 16,000 shares of common stock. On 2026-08-11, 8,000 shares held directly for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration, and 8,000 shares were correspondingly recorded as held indirectly by APNG 1 in connection with the vesting of restricted stock unit awards. Following these transactions, More reports 40,656 shares held directly and 517,917 shares held indirectly through APNG 1, with beneficial ownership of the indirect holdings disclaimed except for his pecuniary interest.
State Street Corporation, through its investment management subsidiaries, reports beneficial ownership of 9,964,151 shares of Vir Biotechnology, Inc. common stock, representing 5.9% of the class as of June 30, 2026. All voting and dispositive authority is held on a shared basis, with 9,678,303 shares subject to shared voting power and 9,964,151 shares subject to shared dispositive power; there is no sole voting or dispositive power. The position is held across affiliated investment advisers including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd. No group or other person is identified as having more than 5% economic interest apart from these affiliated entities.
Vir Biotechnology, Inc. reported a sharp improvement in results for the quarter ended June 30, 2026, driven by a new collaboration with Astellas. Total revenues were $238,946 thousand, up from $1,214 thousand a year earlier, as the company recognized $239.3 million of license and collaboration revenue from the VIR‑5500 Astellas agreement. Net income reached $80,080, compared with a net loss of $110,958 in the prior‑year quarter, or $0.47 diluted earnings per share.
Research and development expenses rose to $135,283 thousand as Vir advanced its hepatitis delta ECLIPSE registrational program and multiple PRO‑XTEN dual‑masked T‑cell engager trials. A February 2026 follow‑on offering raised approximately $162.2 million, contributing to about $1.01 billion in cash, cash equivalents and investments as of June 30, 2026, which management believes is sufficient to fund operations for at least twelve months. Despite the profitable quarter, the company recorded a six‑month net loss of $45,615 while continuing to invest heavily in its infectious disease and oncology pipeline.
Vir Biotechnology, Inc. reported second quarter 2026 results highlighted by $238.9 million in total revenues, primarily license and collaboration revenue from a $240.0 million upfront payment from Astellas, and net income of $80.1 million, or $0.48 per share basic, versus a $111.0 million loss a year earlier.
Cash, cash equivalents and investments were approximately $1.01 billion as of June 30, 2026, after receiving a $75 million equity investment from Astellas and making a $48.0 million pass-through payment to Sanofi; this balance is expected to fund operations into the second half of 2028.
In chronic hepatitis delta, Phase 2 SOLSTICE data showed undetectable HDV RNA in 88% of combination-treated participants at Week 96, with 97% in a last-observation analysis and a generally well tolerated profile. The ECLIPSE registrational program is fully enrolled, with key Phase 3 data expected between late 2026 and early 2027, while the Astellas collaboration advances VIR-5500 and other PRO-XTEN T-cell engagers through multiple Phase 1 dose-expansion cohorts.
Vanguard Portfolio Management, on behalf of certain Vanguard-affiliated entities and managed accounts, reports beneficial ownership of 11,554,377 shares of Vir Biotechnology Inc common stock on an amended Schedule 13G. This represents 6.85% of the class as of June 30, 2026.
The filer has sole voting power over 59,162 shares and sole dispositive power over 11,554,377 shares, with no shared voting or dispositive power. The holdings include securities held by Vanguard funds and other clients over which the reporting entities exercise dispositive and/or voting power.